NeoGenomics earnings shift puts Q2 profitability in focus
NeoGenomics (NEO) returned to profitability in the second quarter of 2026, reporting net income of US$2.24 million on sales of US$201.66 million, compared with a net loss a year earlier.
See our latest analysis for NeoGenomics.
At a share price of US$16.57, NeoGenomics has seen strong momentum build over 2026, with a 90 day share price return of 84.93% and a 1 year total shareholder return of 185.69%. This reflects shifting expectations after the earnings turnaround and updated guidance in late July.
If NeoGenomics’ rebound has your attention, this can be a good moment to look at other diagnostic and treatment focused names using our healthcare AI stock screener, including the 43 healthcare AI stocks.
After an 85% 90-day run and a share price still about 19% below the average analyst target, NeoGenomics now sits between optimism on the turnaround and caution about its remaining full-year loss guidance. Which side is pricing closer to reality?
Most Popular Narrative: 16% Undervalued
At a last close of $16.57 against a narrative fair value of $19.72, NeoGenomics is framed as undervalued, with that gap resting heavily on future earnings power.
Investments in new digital pathology capabilities, automation, and the integration of a unified LIMS are expected to generate material operating efficiencies and enable greater operating leverage, supporting future expansion in EBITDA margins and earnings growth.
Want to see how this margin story is supposed to play out? The narrative leans on steady top line progress and a sharp swing in profitability. Curious which earnings bridge needs to hold up.
Result: Fair Value of $19.72 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, NeoGenomics still faces pressure from declining nonclinical revenues and intense competition in oncology diagnostics, either of which could quickly challenge the current undervalued narrative.
Find out about the key risks to this NeoGenomics narrative.
Another View: NeoGenomics looks expensive on sales multiples
The fair value narrative paints NeoGenomics as 16% undervalued at $19.72, yet the price tag tells a different story. The stock trades on a P/S of 2.8x, compared with 1.5x for the US Healthcare industry, 1.3x for peers, and a fair ratio of 1.5x. That gap points to valuation risk if sentiment cools.
Before leaning too heavily on the story of future margins, it can help to see what the numbers say about this price using the full valuation breakdown, including the fair ratio context, through the See what the numbers say about this price — find out in our valuation breakdown..
Next Steps
If the mix of optimism and caution around NeoGenomics feels finely balanced, this is a good time to check the key risk flags yourself and review the 2 important warning signs.
Looking for more investment ideas beyond NeoGenomics?
If NeoGenomics has sharpened your focus on stock selection, do not stop here. Use the Simply Wall Street Screener to compare other opportunities side by side.
- Hunt for overlooked potential by scanning our screener containing 19 high quality undiscovered gems that pair strong fundamentals with less crowded investor attention.
- Strengthen your downside protection by checking companies in the 78 resilient stocks with low risk scores that score well on resilience and risk controls.
- Target quality with staying power by reviewing the solid balance sheet and fundamentals stocks screener (49 results) that highlight businesses with sturdier financial footing.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com